Trials / Completed
CompletedNCT05314036
The Wellness Transformation Network Pilot Study
Establishment of a Standard Operating Procedure for Screening of the Pathologies Associated With Prediabetes and Diabetes -The Wellness Transformation Network Pilot Study.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- SciMar Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to establish a Standard Operating Procedure (SOP) for the screening of pathologies associated with prediabetes and type 2 diabetes.
Detailed description
The proposed study will enable screening of pathologies associated with cardiometabolic diseases (i.e., hypertension, prediabetes, insulin resistance, diabetes, and obesity). The Meal-Induced Insulinemia and Glycemia (MIG) score will correlate with those dysfunctions that are components of the Absence of Meal-Induced Insulinemia (AMIS) syndrome. Overall the study aims: 1. To establish an SOP for screening pathologies associated with cardiometabolic diseases using a combination of biometrics and metabolomics. 2. To compare a participant's MIG score and hepatalin levels following consumption of a standardized test meal containing macronutrients, and the measurement of several indices of organ health associated with diabetes (i.e., body composition, handgrip strength, spirometry, blood pressure, and heart rate variability). The study will involve 2 study visits: Visit 1 - Screening and Visit 2 - Intervention (Test meal administration and postprandial blood collection).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Standardized test meal | During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal. |
Timeline
- Start date
- 2022-01-17
- Primary completion
- 2022-04-05
- Completion
- 2022-04-05
- First posted
- 2022-04-06
- Last updated
- 2022-04-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05314036. Inclusion in this directory is not an endorsement.